• Tacrine hydrochloride hydrate in AD research

  2026-09-10

  Tacrine hydrochloride hydrate provides a practical benchmark for cholinesterase inhibition, cholinergic signaling, and neuroprotection assays. This guide connects biochemical potency with cell-based workflows, assay controls, troubleshooting, and the multi-target design logic behind next-generation tacrine scaffolds.

• miR-18a, ALOXE3, and Ferroptosis in Glioblastoma

  2026-09-10

  Yang et al. identify a miR-18a/ALOXE3 regulatory axis that links ferroptosis resistance, 12-HETE signaling, glioblastoma migration, and orthotopic tumor progression. The study provides a mechanistic framework for investigating lipid metabolism and regulated cell death as connected drivers of glioblastoma biology, while also highlighting the need to distinguish endogenous ALOXE3 regulation from direct pharmacological GPX4 inhibition.

• Berbamine Hydrochloride: A Pathway-to-Phenotype Guide

  2026-09-09

  Berbamine hydrochloride is a research tool for connecting NF-κB activity, STAT3 signaling, calcium homeostasis, and cancer-cell phenotypes. This guide distinguishes established product evidence from testable hypotheses involving ferroptosis resistance in hepatocellular carcinoma.

• Mouse Neutrophil Cell Isolation Kit for Functional Assays

  2026-09-09

  The Mouse Neutrophil Cell Isolation Kit supports high-purity, activation-sparing preparation for mechanistic immunology and nanomedicine assays. This article explains how negative selection improves interpretation when studying neutrophil-targeted mRNA therapeutics and tumor immunity.

• FDA-Approved Drug Screening Identifies MERS-CoV Inhibitors

  2026-09-08

  de Wilde and colleagues screened 348 FDA-approved compounds in cell culture and identified chloroquine, chlorpromazine, loperamide, and lopinavir as inhibitors of MERS-CoV replication at low-micromolar concentrations. The study demonstrates how phenotypic drug repurposing can rapidly generate antiviral leads for emerging coronaviruses, while also showing why cell-based activity must be separated from target-level and clinical conclusions.

• EPI-001: Reframing AR-Driven Resistance

  2026-09-08

  A translational perspective on EPI-001 as an androgen receptor N-terminal domain inhibitor, connecting AR splice-variant biology, CRPC research, and emerging evidence in AR-positive triple-negative breast cancer.

• Tacrine Hydrochloride Hydrate Workflows

  2026-09-07

  Tacrine hydrochloride hydrate provides a practical benchmark for linking acetylcholinesterase inhibition with cellular neuroprotection. This workflow guide combines concentration planning, orthogonal metabolism checks, and troubleshooting for reproducible Alzheimer’s disease research.

• EZ Cap™ Firefly Luciferase mRNA: Assay Workflows

  2026-09-07

  Build sensitive gene regulation, translation, viability, and imaging assays around a capped, poly(A)-tailed reporter transcript. This practical guide connects product handling with delivery optimization and the latest evidence on trehalose-loaded lipid nanoparticles.

• MMP-2 Liposome Sequential Immunotherapy

  2026-09-05

  The 2023 Acta Pharmaceutica Sinica B study developed an MMP-2-responsive, dual-targeting liposome that sequentially delivers the PD-1 pathway peptide AUNP-12 and the IDO inhibitor NLG919. Its cascade architecture links tumor recognition, enzyme-triggered peptide release, and immunosuppressive microenvironment remodeling in breast cancer models.

• Oltipraz and Nrf2: A Translational MASLD Strategy

  2026-09-04

  Oltipraz offers translational researchers a defined small-molecule route to Nrf2-driven phase II defense. This article connects its established enzyme-induction profile with recent MASLD evidence linking Nrf2, autophagy, and ferroptosis, while separating mechanistic rationale from disease-modifying proof.

• 7-AAD Cell Viability Assay Kit for CAR-T

  2026-09-04

  The 7-AAD Cell Viability Assay Kit provides a membrane-integrity readout for necrotic and late-apoptotic cells in CAR-T research. This 7-amino actinomycin D assay supports flow cytometry viability assay workflows, fluorescence microscopy cell viability studies, and multiplex analysis with complementary markers.

• DR5 Agonists, PD-L1 Stabilization, and Tumor Immunity

  2026-09-03

  The reference study identifies an unexpected immune-evasion response to DR5 agonist antibodies: caspase-8 signaling activates ROCK1 and impairs proteasome function, thereby stabilizing tumor-cell PD-L1. Targeting this DR5–ROCK1–PD-L1 axis improved T-cell activity, tumor regression, and survival in experimental models, providing a mechanistic rationale for combining death-receptor agonism with immune checkpoint strategies.

• Tacrine Hydrochloride Hydrate: An Assay Decision Guide

  2026-09-03

  Tacrine hydrochloride hydrate, also known as Tetrahydroaminacrine, is more than a classic cholinesterase inhibitor. This assay-focused guide explains how to connect enzyme kinetics, cholinergic signaling, cellular neuroprotection, and translational limitations without confusing acute pharmacology with disease modification.

• SCH772984: ERK1/2 Inhibitor Workflow Guide

  2026-09-02

  Build sharper MAPK/ERK pathway inhibition experiments with SCH772984, from phospho-signaling validation to radiosensitivity and xenograft study design. This guide emphasizes assay controls, pathway-aware readouts, dosing logic, and troubleshooting for mutant-driven and radioresistant tumor models.

• O-GlcNAc–HUWE1–TfR1 Axis in Preeclampsia

  2026-09-02

  A 2026 study links reduced placental O-GlcNAc modification to ferroptosis and defective trophoblast syncytialization in preeclampsia. Its central advance is a mechanistic O-GlcNAc–HUWE1–TfR1 pathway that couples protein modification to iron uptake, oxidative injury, and pregnancy outcomes.

8062 records 1/538 page Next 12345 下5页 Last page